Press Release

New Report Shows Benefits of Minnesota Clinical Trials

PhRMA December 13, 2013

MINNEAPOLIS, MN (December 13, 2013) – Working with Minnesota research institutions, including the members of the Minnesota Clinical Research Alliance (MCRA), the nation's biopharmaceutical research companies have conducted 2,945 clinical trials of new medicines since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).  This total reflects an increase of about 300 trials over the last year.

The "Research in Your Backyard:  Pharmaceutical Clinical Trials in Minnesota" report was  released today at a meeting of LifeScience Alley, a life sciences trade association whose members employ about 250,000 Minnesotans.  The report shows Minnesota's clinical trials have targeted the most debilitating chronic diseases, including cancer, diabetes, heart disease and stroke, and a wide range of other conditions, including allergies, sinusitis, migraine headaches, pneumonia and pain.

"The state's clinical trials have benefited patients, the economy and the advancement of science," said Jeff Trewhitt, a PhRMA spokesman and co-author of the report.  “Biopharmaceutical companies and their collaborators are in a research partnership that helps to support the work of talented local scientists and facilitates the discovery and development of new medicines.”    

More than 400 of the trials are still active and recruiting patients, giving some disease sufferers an additional treatment option to discuss with health care providers and local clinicians conducting clinical research.  For patients interested in exploring clinical trials, the new report’s appendix provides a helpful step for getting more information about Minnesota’s trials.       

Minnesotans can also learn about the state's clinical research from the MCRA, which has educated patients, legislators, policymakers and others about clinical trials for the last three years.  The companies that belong to MCRA, including Minnesota Diet Research Center/Frestedt Inc. in St. Louis Park, Clinical Research Institute in Minneapolis and Plymouth, Prism Clinical Research in St. Paul and MAPS Applied Research Center in Edina, conduct many of the state's trials of both new medicines and medical devices.

The partnerships between biopharmaceutical companies and MCRA members and other local research institutions, including the University of Minnesota Medical School in Minneapolis and Duluth and Mayo Medical School in Rochester, allow local clinicians and disease researchers to be involved in cutting-edge research of new medicines.

Clinical research has been conducted at university medical schools, local hospitals, specialty treatment centers and contract research organizations in more than a dozen Minnesota communities. 

The medicines clinically tested in the state have included cutting-edge biotechnology treatments, including a genetically modified virus-based vaccine to treat melanoma, a monoclonal antibody for the treatment of cancer and a recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.

For more information on the "Research in Your Backyard" report, including locations of Minnesota clinical trials, click here.     

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit